Advances of treatment with IL-6/IL-6 receptor inhibitors for RA

Study of Oral Gold ( Auranofin ) in Treatment of Iranian Patient with Rheumatoid Arthritis (RA). Preliminary Report of 6 Months Treatment

28 patients with classical / definite RA entered to a prospective open study evaluating efficacy and side effects of Auranofin. 21 patients completed 6 months of therapy with 6 mg Auranofin daily. Parameters of disease activity including Joint Tenderness Score, Joint Swelling Score, Walking Time and duration of Morning Stiffness improved significantly after 6 months (p<0.001). Grip strength, Su...

Rituximab for Treatment of Hemophilia A with High-Responder Inhibitors

Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in lowering or eliminating the ...

comparison of zoe and vitapex for canal treatment of necrotic primary teeth

چکیده ندارد.

Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

By using a sandwich ELISA, soluble human IL-6 receptor (sIL-6 R) levels were measured in the sera of 20 healthy children and of 25 patients with systemic juvenile rheumatoid arthritis (JRA). In patients with systemic JRA, serum sIL-6 R levels (114.6 +/- 37.7 ng/ml) were significantly lower (P < 0.01) than those of healthy children (161.2 +/- 45.5 ng/ml). Serum sIL-6 R levels were negatively cor...

The New and Evolving Science of IL-6 in Rheumatoid Arthritis Neutrophils in RA and the Role of IL-6